Pharmafile Logo
Pharmafocus logo
Advanced Search

afatinib

Showing 11 posts of 11 posts found.

BI image

Boehringer and Sanofi admit to code breaches

February 13, 2015
Medical Communications, Sales and Marketing ABPI, Boehringer, PMCPA, Sanofi, afatinib, giotrif

Sanofi and Boehringer Ingelheim have both admitted to breaching the ABPI Code of Practice, with Sanofi set to be publicly …

News
boehringer image

Boehringer lung cancer drug shows survival benefit

June 3, 2014
Sales and Marketing ASCO, Boehringer, NSCLC, afatinib, giotrif, lung cancer

A new analysis of two late-stage trials shows that Boehringer drug Giotrif extends overall survival in a large proportion of …

News
boehringer_angle_22

Giotrif increases lung cancer survival

May 16, 2014
Research and Development, Sales and Marketing Boehringer, Iressa, Roche, Tarceva, afatinib, giotrif, lung cancer

Boehringer Ingelheim is trumpeting overall survival results from a new analysis of two late-stage studies involving Giotrif in lung cancer …

News

Boehringer’s first cancer drug gains NICE yes

March 17, 2014
Sales and Marketing Boehringer, Cancer, NICE, NSCLC, afatinib, giotrif

NICE is recommending that Boehringer Ingelheim’s first oncology treatment Giotrif be funded by the NHS. The new final draft guidance …

News

Boehringer nears European approval for first cancer drug

July 29, 2013
Sales and Marketing Boehringer, Cancer, FDA, afatinib

Boehringer’s first cancer drug is just months away from being approved in Europe after a committee for the EMA gave …

News
boehringer_german_building_at_night_5

FDA approves Boehringer’s lung cancer drug

July 12, 2013
Medical Communications, Sales and Marketing Boehringer, FDA, Roche, Tarceva, afatinib, lung cancer

Boehringer Ingelheim’s late-stage lung cancer drug Gilotrif has received an accelerated FDA approval for patients with a certain genetic mutation. …

News

Boehringer submits new lung cancer drug

September 20, 2012
Research and Development, Sales and Marketing Boehringer, NSCLC, Roche, Tarceva, afatinib

Boehringer Ingelheim has filed its new lung cancer drug with the EMA. Afatinib is the latest targeted therapy for lung …

News
Boehringer picture

Boehringer broadens afatinib studies

January 27, 2012
Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, afatinib

Boehringer Ingelheim is expanding the scope of its studies into afatinib to test its use against head and neck cancers. …

News

Boehringer expands afatinib breast cancer trials

August 31, 2011
Research and Development Boehringer, afatinib

Boehringer Ingelheim has begun two new phase II trials of its investigational cancer drug afatinib. The studies will cover afatinib’s …

News
Lung cancer cells

No magic bullet, but a growing arsenal against lung cancer

February 23, 2011
Research and Development ASA404, Cancer, Iressa, NSCLC, Tarceva, afatinib, crizotinib, figitumumab, lung cancer, non small cell lung cancer, non-small cell lung cancer

A man in his 70s is waiting for his appointment with the oncologist after being referred there by his family …

Feature

Boehringer puts afatinib head-to-head with Herceptin

December 10, 2010
Research and Development BIBW 2992, Boehringer Ingelheim, Herceptin, Roche, Tovok, afatinib, breast cancer

Boehringer Ingelheim has set up a showdown between one of its pipeline oncology products and Roche’s Herceptin. It has started …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024